Results 181 to 190 of about 105,476 (242)

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 2, Page 354-366, February 2026.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu   +9 more
wiley   +1 more source

The HRAS Variant c.175G>A (p.Ala59Thr) Causes a Predominantly Ectodermal Phenotype Lacking Classic Costello Syndrome Features

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 2, Page 407-418, February 2026.
ABSTRACT Costello syndrome (CS) is a rare dominant HRAS RASopathy characterized by curly hair, cardiac abnormalities, craniofacial anomalies, and developmental delay. HRAS codon 58, 59, and 60 variants are associated with milder phenotypes. We describe a three‐generation family with a previously unreported heterozygous HRAS variant c.175G>A (p.Ala59Thr)
Nikole Rautiainen   +10 more
wiley   +1 more source

GLP‐1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study

open access: yesBJUI Compass, Volume 7, Issue 2, February 2026.
Abstract Objectives The purpose of this study is to investigate the impact of Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) use on 90‐day postoperative outcomes and overall survival following partial nephrectomy (PN) for renal cell carcinoma (RCC), where type 2 diabetes mellitus (T2DM) is a common comorbidity.
Sam Kwon   +7 more
wiley   +1 more source

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 579-588, February 2026.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman   +13 more
wiley   +1 more source

Atrial Dilated Cardiomyopathy: From Molecular Pathogenesis to Clinical Implications. [PDF]

open access: yesJ Clin Med
Carella MC   +14 more
europepmc   +1 more source

An Atypical Presentation of Tubulointerstitial Nephritis With Uveitis (TINU) in an Older Patient Requiring Emergency Dialysis: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Tubulointerstitial nephritis with uveitis (TINU) is an immune‐mediated systemic disorder most commonly described in adolescents and young adults, and its recognition in older patients remains challenging. We report the case of a 58‐year‐old woman who presented with systemic symptoms and rapidly progressive acute kidney injury.
Yuli Yang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy